Cargando…

Developing a novel treatment for patients with chronic pain and Opioid User Disorder

BACKGROUND: It is critical to develop empirically based, community-treatment friendly, psychotherapy interventions to improve treatment for patients with comorbid chronic pain and Opioid Use Disorder. Understanding factors that increase patient adherence and attendance is important, along with strat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachholtz, Amy, Robinson, Dallas, Epstein, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077914/
https://www.ncbi.nlm.nih.gov/pubmed/35525964
http://dx.doi.org/10.1186/s13011-022-00464-4
_version_ 1784702215416446976
author Wachholtz, Amy
Robinson, Dallas
Epstein, Elizabeth
author_facet Wachholtz, Amy
Robinson, Dallas
Epstein, Elizabeth
author_sort Wachholtz, Amy
collection PubMed
description BACKGROUND: It is critical to develop empirically based, community-treatment friendly, psychotherapy interventions to improve treatment for patients with comorbid chronic pain and Opioid Use Disorder. Understanding factors that increase patient adherence and attendance is important, along with strategies targeted to address those issues. METHODS: Based on initial psychophysiology research on adults with OUD and chronic pain, we created an integrated cognitive-behavioral, 12-week outpatient group therapy called STOP (Self-regulation Therapy for Opioid addiction and Pain). In this study, we pilot tested STOP in a Stage 1a feasibility and acceptability study to identify unique treatment needs and factors that increased session attendance, adherence to treatment, and improved outcomes. Fourteen individuals on medication for OUD with co-occurring chronic pain participated. RESULTS: STOP had high attendance rates (80%; and active patient engagement). Urine toxicology showed no illicit drug use after week 8. Data analysis from pre-intervention to a 3-month follow-up showed significant functional improvement (F(1,12) = 45.82;p < 0.001) and decreased pain severity levels (F(1,12) = 37.62;p < 0.01). Participants reported appreciation of the unique tools to counteract physiological activation during a pain flare or craving. Participants also reported benefit from in-session visual aids, applicable pain psychology information, take-home worksheets, tools for relaxation practice, learning to apply the therapy tools. DISCUSSION: STOP is a 90-min 12-week rolling-entry group therapy based on previous research identifying psychophysiological needs of pain and OUD patients that can be seamlessly incorporated into community addiction treatment clinics. CONCLUSION: Preliminary results of STOP are promising with high patient engagement and adherence and significant reductions in drug use and pain. TRIAL REGISTRATION: ClinicalTrials.Gov NCT03363243, Registered Dec 6, 2017.
format Online
Article
Text
id pubmed-9077914
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90779142022-05-08 Developing a novel treatment for patients with chronic pain and Opioid User Disorder Wachholtz, Amy Robinson, Dallas Epstein, Elizabeth Subst Abuse Treat Prev Policy Research BACKGROUND: It is critical to develop empirically based, community-treatment friendly, psychotherapy interventions to improve treatment for patients with comorbid chronic pain and Opioid Use Disorder. Understanding factors that increase patient adherence and attendance is important, along with strategies targeted to address those issues. METHODS: Based on initial psychophysiology research on adults with OUD and chronic pain, we created an integrated cognitive-behavioral, 12-week outpatient group therapy called STOP (Self-regulation Therapy for Opioid addiction and Pain). In this study, we pilot tested STOP in a Stage 1a feasibility and acceptability study to identify unique treatment needs and factors that increased session attendance, adherence to treatment, and improved outcomes. Fourteen individuals on medication for OUD with co-occurring chronic pain participated. RESULTS: STOP had high attendance rates (80%; and active patient engagement). Urine toxicology showed no illicit drug use after week 8. Data analysis from pre-intervention to a 3-month follow-up showed significant functional improvement (F(1,12) = 45.82;p < 0.001) and decreased pain severity levels (F(1,12) = 37.62;p < 0.01). Participants reported appreciation of the unique tools to counteract physiological activation during a pain flare or craving. Participants also reported benefit from in-session visual aids, applicable pain psychology information, take-home worksheets, tools for relaxation practice, learning to apply the therapy tools. DISCUSSION: STOP is a 90-min 12-week rolling-entry group therapy based on previous research identifying psychophysiological needs of pain and OUD patients that can be seamlessly incorporated into community addiction treatment clinics. CONCLUSION: Preliminary results of STOP are promising with high patient engagement and adherence and significant reductions in drug use and pain. TRIAL REGISTRATION: ClinicalTrials.Gov NCT03363243, Registered Dec 6, 2017. BioMed Central 2022-05-07 /pmc/articles/PMC9077914/ /pubmed/35525964 http://dx.doi.org/10.1186/s13011-022-00464-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wachholtz, Amy
Robinson, Dallas
Epstein, Elizabeth
Developing a novel treatment for patients with chronic pain and Opioid User Disorder
title Developing a novel treatment for patients with chronic pain and Opioid User Disorder
title_full Developing a novel treatment for patients with chronic pain and Opioid User Disorder
title_fullStr Developing a novel treatment for patients with chronic pain and Opioid User Disorder
title_full_unstemmed Developing a novel treatment for patients with chronic pain and Opioid User Disorder
title_short Developing a novel treatment for patients with chronic pain and Opioid User Disorder
title_sort developing a novel treatment for patients with chronic pain and opioid user disorder
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077914/
https://www.ncbi.nlm.nih.gov/pubmed/35525964
http://dx.doi.org/10.1186/s13011-022-00464-4
work_keys_str_mv AT wachholtzamy developinganoveltreatmentforpatientswithchronicpainandopioiduserdisorder
AT robinsondallas developinganoveltreatmentforpatientswithchronicpainandopioiduserdisorder
AT epsteinelizabeth developinganoveltreatmentforpatientswithchronicpainandopioiduserdisorder